Banner
Biotechnology

Amgen, Inc. (Nasdaq: AMGN) – FYE 12/2019 SELL HALF – The stock is currently trading at levels at or above my most recent $225 reduce target, but below my most recent $288 terminate target. Please See Linked Worksheet
Revised on 02/13/2020

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) – FYE 12/2019 – UNDER VALUED – The stock is currently trading at levels below my most recent $103 initiate target. Please See Linked PDF Worksheet
Revised on 03/21/2020

Gilead Sciences, Inc. (Nasdaq: GILD) – FYE 12/2019 – SELL HALF – The stock is currently trading at levels at or above my most recent $67 reduce target, but below my most recent $86 terminate target. Please See Linked PDF Worksheet
Revised on 03/23/2020

Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) – FYE 12/2019 – OVER VALUED – The stock is currently trading at levels above my most recent $371 terminate target. Please See Linked PDF Worksheet
Revised on 03/24/2020

Repligen Corporation (Nasdaq: RGEN) – FYE 12/2019 – OVER VALUED – The stock is currently trading at levels above my most recent $34 terminate target. Please See Linked PDF Worksheet
Revised on 03/25/2020

Please note that worksheets are updated basis the most current SEC 10-K ANNUAL filing.